Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The rapid transformation of China's pharmaceutical and biotech sector reveals the changing face of this nation and the realization that China is more dynamic than developed markets such as the U.S. and Europe and is a good place to try out different models and approaches to R&D, presenters at the China R&D Summit told attendees April 7

You may also be interested in...



PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)

Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.

PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)

Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.

PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)

Babiss speaks of the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D.

Related Content

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel